Maine’s Prescription Monitoring Program

Goals and Benefits
22nd Annual Maine Pain Symposium
May 1st, 2019
Introduction

• Maine Department of Health and Human Services

• Office of Substance Abuse and Mental Health Services

• Johanna Buzzell – Information and Data Systems Manager

• Jennifer Marlowe – PMP and IT Systems Project Coordinator
Maine PMP’s Mission Statement

Goals of State PMPs

Benefits of Utilizing the PMP

Provider Comparison Reports
To improve public health by preventing and deterring adverse prescription drug related events by enabling healthcare professionals to review their patient’s controlled substance prescription history prior to prescribing or dispensing and educating healthcare professionals and patients on safe and effective pain management therapies, including alternatives to prescription drugs.
Goals of State PMPs

- Education and Information
- Public Health Initiatives
- Early Intervention and Prevention
Education and Information

• Feedback to prescribers and pharmacists
  • Patient history
  • Physician history
    • This feature has aided a number of prescribers in identifying individuals who have fraudulently used their DEA number in an effort to illicitly obtain opioids or other prescription drugs

• Prescribing trend analysis
  • PMP data paired with other datasets has helped inform resource allocation for state entities

• Increase in general awareness of prescription drug diversion and illicit use of pharmaceuticals
Public Health Initiatives

- Resource allocation
- “Hot Spotting”
- Emerging threats
- Inform policy changes
Early Intervention and Prevention

- Identify potential diversion activities
- Identify possible “doctor shoppers”
- Identify problematic prescribing
Benefits of Utilizing the PMP

• Improved quality of care
  • Reduction in harmful drug interactions
  • More complete and accurate patient history

• Heightened opportunities to intervene and deter potential misuse or dependence

• Improved population health
  • Geographic trends
  • “High Burden” communities

• Opportunities to self-audit and manage one’s own prescribing trends
Prescriber Reports
(Peer Comparison)
General Opioid Prescription Information

Prescriber Information

Number of persons for whom you prescribed at least one (1) opioid
Your monthly average

Peer group comparisons are medians versus averages

Number of opioid prescriptions written by you.
Your monthly average
Top Medications and Prescriptions by MME

Top three (3) medication prescribed by you based on number of prescriptions

**TOP MEDICATIONS PRESCRIBED (FULL REPORT PERIOD)**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocodone Bitartrate/Acetaminophen</td>
<td>70%</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>80%</td>
</tr>
<tr>
<td>Zolpidem Tartrate</td>
<td>60%</td>
</tr>
</tbody>
</table>

**PRESCRIPTIONS BY MME (MORPHINE MILLIGRAM EQUIVALENT) (FULL REPORT PERIOD)**

- **MME 0-50**: 70%, 80%, 60%
- **MME 51-90**: 20%, 10%, 15%, 5%
- **MME 91-200**: 5%, 5%, 15%, 5%
- **MME >200**: 5%, 5%, 10%

Percentage of opioid analgesic prescriptions written by you in the following daily MME ranges:

- 0 – 50
- 51 – 90
- 91 – 200
- >200

Percentages reflect the full report period
Opioid Treatment Duration

Percentage of your patients where their opioid treatment duration falls into one of the indicated ranges of days. These values are based on the cumulative days of supply of a person’s prescriptions during the report period.
Prescription Volumes

Total Morphine Milligram Equivalency (MME) of prescriptions written by you in the following groups:

- Total MME of Oxycodone containing products
- Total MME of Hydrocodone containing products
- Total MME of all other opioids

Value is Monthly Average
Anxiolytic/Sedative/Hypnotic Prescribing

Number of Anxiolytic / Sedative / Hypnotic prescriptions (together as one group)

Quantity of dose units of Anxiolytic / Sedative / Hypnotic prescriptions (together as one group)

Values are monthly averages

ANXIOLYTIC / SEDATIVE / HYPNOTIC PRESCRIBING (MONTHLY AVERAGE)
### PMP Usage and Patients Exceeding Multiple Provider Threshold

<table>
<thead>
<tr>
<th>PDMP USAGE (MONTHLY AVERAGE)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>POMP REQUESTS BY YOU</td>
<td>100</td>
</tr>
<tr>
<td>POMP REQUESTS BY YOUR DELEGATE(S)</td>
<td>75</td>
</tr>
<tr>
<td>SIMILAR PRESCRIBER AVERAGE</td>
<td>200</td>
</tr>
<tr>
<td>SPECIALTY FIELD AVERAGE</td>
<td>150</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PATIENTS EXCEEDING MULTIPLE PROVIDER THRESHOLDS (FULL REPORT PERIOD)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PATIENTS EXCEEDING MULTIPLE PRESCRIBER THRESHOLD</td>
<td>25</td>
</tr>
<tr>
<td>PATIENTS EXCEEDING MULTIPLE PHARMACY THRESHOLD</td>
<td>15</td>
</tr>
</tbody>
</table>

Number of patients with prescriptions from > 5 prescribers (including at least one written by you)

Number of patients having prescriptions filled at > 5 pharmacies (including at least one written by you)
### Dangerous Combo Therapy

<table>
<thead>
<tr>
<th>COMBO PRESCRIPTIONS FOR OPIOID + BENZO IN SAME MONTH</th>
<th>COMBO PRESCRIPTIONS FOR OPIOID + BENZO + CARISOPRODOL IN SAME MONTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 BY YOU</td>
<td>15 BY YOU</td>
</tr>
<tr>
<td>35 BY YOU + OTHER PRESCRIBERS</td>
<td>20 BY YOU + OTHER PRESCRIBERS</td>
</tr>
</tbody>
</table>

- Number of patients receiving an opioid + a benzodiazepine in the same month - both written by you
- Number of patients receiving an opioid + a benzodiazepine + Carisoprodol in the same month – all written by you
- Number of patients receiving an opioid + a benzodiazepine in the same month – where you wrote one
- Number of patients receiving an opioid + a benzodiazepine + Carisoprodol in the same month – where you wrote one
Questions?

Johanna Buzzell
Information and Data Systems Manager
Johanna.Buzzell@maine.gov

Jennifer Marlowe
PMP and IT Systems Project Coordinator
Jennifer.Marlowe@maine.gov